Published in Cancer Weekly, July 25th, 2006
SciGen announced previously that it had signed an exclusive worldwide agreement with ACL Biopharm, Intas research and development partner, for the bulk supply of GCSF and EPO.
The technology transfer agreement will now allow SciGen to manufacture its own product supplies for commercialization using its existing and future sale and marketing channels. The world...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.